Guggenheim initiated coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $18.00 target price on the stock.
Separately, Evercore ISI began coverage on shares of Mirum Pharmaceuticals in a report on Monday. They set an outperform rating and a $25.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and an average price target of $25.00.
NASDAQ:MIRM opened at $13.45 on Monday. Mirum Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $15.50.
In other Mirum Pharmaceuticals news, insider James E. Flynn bought 332,000 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,980,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Patrick J. Heron bought 450,000 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were acquired at an average price of $15.00 per share, with a total value of $6,750,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,357,000 shares of company stock valued at $20,355,000 over the last 90 days.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: What are economic reports?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.